Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Cardiovascular Diseases Clinical Trial

— Lirabolic  

Official title:

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04057261
• Other study ID #: 17-162
• Status: Withdrawn
• Phase: Phase 3
• Start date: November 2020
• Est. completion date: November 2022

Study information

• Verified date: March 2021
• Source: RWTH Aachen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In an unbiased metabolomics approach with subsequent pathway analyses, the current study seeks to examine the effect of Liraglutide treatment on the metabolic signature in treated patients as well as the effect of Liraglutide on various echocardiographic parameters of cardiac function and rhythm profile, thus paving the way for future research to explain the effects of Liraglutide on cardiovascular mortality and overall mortality in treated patients.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Type 2 diabetes

2. Serum levels of HbA1c = 7,0%

3. Age = 18 years

4. Patients with existing cardiovascular disease: coronary heart disease, cerebrovascular disease, peripheral vascular disease, chronic kidney disease of stage III or chronic heart failure of NYHA II or III)

5. Written informed consent prior to study participation

Exclusion Criteria:

1. Type 1 diabetes

2. Treatment with GLP-1 receptor agonists or DPP-4 inhibitors within the last 4 weeks

3. Patients with familiar or personal history of multiple endocrine neoplasia-type 2 or medullary C-cell cancer

4. Renal impairment (eGFR < 30 mL/min)

5. Occurrence of acute vascular events within 6 weeks before screening and randomization

6. Known or suspected hypersensitivity to Liraglutide

7. Pregnant females as determined by positive (serum or urine) hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol.

8. Lactating females

9. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.

10. The subject received an investigational drug within 30 days prior to inclusion into this study.

11. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study.

12. The subject is unwilling or unable to follow the procedures outlined in the protocol.

13. The subject is mentally or legally incapacitated.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• Liraglutide Pen Injector [Victoza]
Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
• Placebo
Matching Placebo once daily, subcutaneous injection via pre-filled pen.

Locations

Country	Name	City	State
Germany	Department of Internal Medicine I, University Hospital	Aachen

Sponsors (2)

Lead Sponsor	Collaborator
RWTH Aachen University	Novo Nordisk A/S

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months	Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months measured by a platform including 2 separate reverse phase (RP)/UPLC-MS/MS with positive ion mode electrospray ionization (ESI), (RP)/UPLC-MS/MS with negative ESI, and (HILIC)/UPLC-MS/MS with negative ESI.	3 month
Secondary	change in left ventricular diastolic function	change in left ventricular diastolic function between baseline and after 12 weeks as determined by 2D and 3D parameter global Strain Rate E by echocardiography	3 month
Secondary	change in left ventricular diastolic function	change in left ventricular diastolic function between baseline and after 12 weeks as determined by standardized parameter E/é and left atrial (LA) volume by echocardiography	3 month
Secondary	change in left ventricular systolic function	change in left ventricular systolic function by ejection fraction (EF) by echocardiography	3 month
Secondary	Changes in systolic and diastolic blood pressure (mmHg)	Changes in systolic and diastolic blood pressure (mmHg) between Liraglutide treatment group and placebo group after 1 and 3 months.	3 month
Secondary	body weight		3 month
Secondary	Changes in NT-proBNP serum levels (pg/ml)	Changes in NT-proBNP serum levels (pg/ml) between Liraglutide treatment group versus placebo group after 1 and 3 months.	3 month
Secondary	Differences of the serum lipid profile between Liraglutide treatment group and placebo group	Differences of the serum lipid profile including serum levels of triglycerides (mg/dl), total cholesterol (mg/dl), low-density lipoprotein cholesterol (mg/dl) and high-density lipoprotein cholesterol (mg/dl)between Liraglutide treatment group and placebo group after 1 and 3 months	3 month
Secondary	changes of serum levels of glucose, HbA1c, glucagon, insulin, C-Peptide, ß-Hydroxybutyrate between Liraglutide treatment group and placebo group	Changes in serum levels of glucose (mg/dl), HbA1c (%), glucagon (pg/ml), insulin (ng/ml), C-Peptide (ng/ml), ß-Hydroxybutyrate (mmol/l) between Liraglutide treatment group and placebo group after 1 and 3 months	3 month
Secondary	Heart rate variability	Differences in heart rate variability measured by 24 hour ECG between Liraglutide treatment group and placebo group after 3 month including the following parameters: mean heart rate (bpm), maximum/minimum heart rate (bpm) and long-term variation of RR intervals (defined as standard deviation over 24 hours of per-minute means of RR intervals).	3 month
Secondary	Resting energy expenditure	Resting energy expenditure measured by indirect calorimetry [CardioCoach CO2]	3 month
Secondary	Respiratory Exchange Ratio	Respiratory Exchange Ratio measured by indirect calorimetry [CardioCoach CO2]	3 month
Secondary	Differences in gut microbiome composition measured by 16S rRNA targeted gene sequencing of feces between Liraglutide treatment group and placebo group	Differences in gut microbiome composition measured by 16S rRNA targeted gene sequencing of feces between Liraglutide treatment group and placebo group after 1 and 3 month including the following parameters: alpha diversity (reported as Shannon diversity index) and differences in bacterial composition at different taxonomic levels including genus, family and class of bacteria (reported as relative abundance).	3 month
Secondary	Albumin excretion	Albumin excretion by 24 h urine collection	3 month
Secondary	changes in inflammasome analyses	Differences in serum levels of inflammatory cytokines including C-reactive protein (mg/ml), Interleukin 6 (pg/ml), Interleukin 1 beta (pg/ml) and tumor necrosis factor alpha (pg/ml) between Liraglutide treatment group and placebo group after 1 and 3 month	3 month
Secondary	Differences in circulation inflammatory cell composition by flow cytometry analyses (FACS) between Liraglutide treatment group and placebo group	Differences in circulation inflammatory cell composition by flow cytometry analyses (FACS) between Liraglutide treatment group and placebo group after 1 and 3 month including the following parameters: Numbers of T-cells including T-cell subsets and monocytes including monocyte subsets. Numbers will be reported as percentage of parent, i.e. total pool of CD45+ immune cells).	3 month